The influenza virus causes acute
respiratory infections, leading to high morbidity and mortality in groups of patients at higher risk.
Antiviral drugs represent the first line of defense against
influenza, both for seasonal
infections and pandemic outbreaks. Two main classes of drugs against
influenza are in clinical use: M2-channel blockers and
neuraminidase inhibitors. Nevertheless, because
influenza strains that are resistant to these
antivirals have been described, the search for novel compounds with different mechanisms of action is necessary. Here, we investigated the anti-
influenza activity of a fungi-derived
natural product,
aureonitol. This compound inhibited
influenza A and B virus replication. This compound was more effective against
influenza A(H3N2), with an EC50 of 100 nM.
Aureonitol cytoxicity was also very low, with a CC50 value of 1426 μM.
Aureonitol inhibited
influenza hemagglutination and, consequently, significantly impaired virus adsorption. Molecular modeling studies revealed that
aureonitol docked in the
sialic acid binding site of
hemagglutinin, forming hydrogen bonds with highly conserved residues. Altogether, our results indicate that the chemical structure of
aureonitol is promising for future anti-
influenza drug design.